Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2019

01-06-2019

Intracellular pH dynamics and charge-changing somatic mutations in cancer

Authors: Katharine A. White, Kyle Kisor, Diane L. Barber

Published in: Cancer and Metastasis Reviews | Issue 1-2/2019

Login to get access

Abstract

An unresolved question critical for understanding cancer is how recurring somatic mutations are retained and how selective pressures drive retention. Increased intracellular pH (pHi) is common to most cancers and is an early event in cancer development. Recent work shows that recurrent somatic mutations can confer an adaptive gain in pH sensing to mutant proteins, enhancing tumorigenic phenotypes specifically at the increased pHi of cancer. Newly identified amino acid mutation signatures in cancer suggest charge-changing mutations define and shape the mutational landscape of cancer. Taken together, these results support a new perspective on the functional significance of somatic mutations in cancer. In this review, we explore existing data and new directions for better understanding how changes in dynamic pH sensing by somatic mutation might be conferring a fitness advantage to the high pH of cancer.
Literature
1.
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011). Dysregulated pH: a perfect storm for cancer progression. Nature Reviews Cancer, 11, 671–677.CrossRefPubMed
2.
White, K. A., Grillo-Hill, B. K., & Barber, D. L. (2017). Cancer cell behaviors mediated by dysregulated pH dynamics at a glance. Journal of Cell Science, 130, 663–669.CrossRefPubMedPubMedCentral
3.
Pedersen, S. F., & Stock, C. (2013). Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Research, 73, 1658–1661.CrossRefPubMed
4.
Parks, S. K., Chiche, J., & Pouyssegur, J. (2013). Disrupting proton dynamics and energy metabolism for cancer therapy. Nature Reviews Cancer, 13, 611–623.CrossRefPubMed
5.
Reshkin, S. J., et al. (2000). Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. The FASEB Journal, 14, 2185–2197.CrossRefPubMed
6.
Grillo-Hill, B. K., Choi, C., Jimenez-Vidal, M., & Barber, D. L. (2015). Increased H(+) efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression. Elife, 4.
7.
8.
9.
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012). Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer, 12, 487–493.CrossRefPubMedPubMedCentral
10.
Ward, S. G., & Mrsny, R. (2009). New insights into mechanisms of gastrointestinal inflammation and cancer. Current Opinion in Pharmacology, 9, 677–679.CrossRefPubMed
11.
Ramachandran, S., Ient, J., Gottgens, E. L., Krieg, A. J., & Hammond, E. M. (2015). Epigenetic therapy for solid tumors: highlighting the impact of tumor hypoxia. Genes Basel, 6, 935–956.CrossRefPubMedPubMedCentral
12.
Brahimi-Horn, M. C., Bellot, G., & Pouyssegur, J. (2011). Hypoxia and energetic tumour metabolism. Current Opinion in Genetics & Development, 21, 67–72.CrossRef
13.
14.
Su, A. I., et al. (2001). Molecular classification of human carcinomas by use of gene expression signatures. Cancer Research, 61, 7388–7393.PubMed
15.
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P. A., Kaminker, J. S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J. K. V., Sukumar, S., Polyak, K., Park, B. H., Pethiyagoda, C. L., Pant, P. V. K., Ballinger, D. G., Sparks, A. B., Hartigan, J., Smith, D. R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S. D., Parmigiani, G., Kinzler, K. W., Velculescu, V. E., & Vogelstein, B. (2007). The genomic landscapes of human breast and colorectal cancers. Science, 318, 1108–1113.CrossRefPubMed
16.
17.
Watanabe, N., Okochi, E., Mochizuki, M., Sugimura, T., & Ushijima, T. (2001). The presence of single nucleotide instability in human breast cancer cell lines. Cancer Research, 61, 7739–7742.PubMed
18.
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., Widaa, S., Hinton, J., Fahey, C., Fu, B., Swamy, S., Dalgliesh, G. L., Teh, B. T., Deloukas, P., Yang, F., Campbell, P. J., Futreal, P. A., & Stratton, M. R. (2010). Signatures of mutation and selection in the cancer genome. Nature, 463, 893–898.CrossRefPubMedPubMedCentral
19.
Szpiech, Z. A., Strauli, N. B., White, K. A., Ruiz, D. G., Jacobson, M. P., Barber, D. L., & Hernandez, R. D. (2017). Prominent features of the amino acid mutation landscape in cancer. PLoS One, 12, e0183273.CrossRefPubMedPubMedCentral
20.
Anoosha, P., Sakthivel, R., & Michael Gromiha, M. (2016). Exploring preferred amino acid mutations in cancer genes: applications to identify potential drug targets. Biochimica et Biophysica Acta, 1862, 155–165.CrossRefPubMed
21.
Tan, H., Bao, J., & Zhou, X. (2015). Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Scientific Reports, 5, 12566.CrossRefPubMedPubMedCentral
22.
23.
Pollock, D. D., Thiltgen, G., & Goldstein, R. A. (2012). Amino acid coevolution induces an evolutionary stokes shift. Proceedings of the National Academy of Sciences, 109, E1352–E1359.CrossRef
24.
White, K. A., Ruiz, D. G., Szpiech, Z. A., Strauli, N. B., Hernandez, R. D., Jacobson, M. P., & Barber, D. L. (2017). Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins. Science Signaling, 10, eaam9931.CrossRefPubMedPubMedCentral
25.
Frantz, C., Barreiro, G., Dominguez, L., Chen, X., Eddy, R., Condeelis, J., Kelly, M. J. S., Jacobson, M. P., & Barber, D. L. (2008). Cofilin is a pH sensor for actin free barbed end formation: role of phosphoinositide binding. The Journal of Cell Biology, 183, 865–879.CrossRefPubMedPubMedCentral
26.
Srivastava, J., Barreiro, G., Groscurth, S., Gingras, A. R., Goult, B. T., Critchley, D. R., Kelly, M. J. S., Jacobson, M. P., & Barber, D. L. (2008). Structural model and functional significance of pH-dependent talin-actin binding for focal adhesion remodeling. Proceedings of the National Academy of Sciences of the United States of America, 105, 14436–14441.CrossRefPubMedPubMedCentral
27.
Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11, 217–227.CrossRefPubMedPubMedCentral
28.
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., Stefancsik, R., Harsha, B., Kok, C. Y., Jia, M., Jubb, H., Sondka, Z., Thompson, S., de, T., & Campbell, P. J. (2017). COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Research, 45, D777–D783.CrossRefPubMed
29.
Joerger, A. C., & Fersht, A. R. (2010). The tumor suppressor p53: from structures to drug discovery. Cold Spring Harbor Perspectives in Biology, 2, a000919.CrossRefPubMedPubMedCentral
30.
Shi, Y., & Massagué, J. (2003). Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell, 113, 685–700.CrossRefPubMed
31.
Singh, P., Srinivasan, R., & Wig, J. D. (2012). SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas, 41, 541–546.CrossRefPubMed
32.
Papageorgis, P., Cheng, K., Ozturk, S., Gong, Y., Lambert, A. W., Abdolmaleky, H. M., Zhou, J. R., & Thiagalingam, S. (2011). Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Research, 71, 998–1008.CrossRefPubMedPubMedCentral
33.
Schiro, M. M., Stauber, S. E., Peterson, T. L., Krueger, C., Darnell, S. J., Satyshur, K. A., Drinkwater, N. R., Newton, M. A., & Hoffmann, F. M. (2011). Mutations in protein-binding hot-spots on the hub protein Smad3 differentially affect its protein interactions and Smad3-regulated gene expression. PLoS One, 6, e25021.CrossRefPubMedPubMedCentral
34.
Linder, P., & Jankowsky, E. (2011). From unwinding to clamping—the DEAD box RNA helicase family. Nature Reviews Molecular Cell Biology, 12, 505–516.CrossRefPubMed
35.
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y. J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., & Pfister, S. M. (2012). Medulloblastomics: the end of the beginning. Nature Reviews. Cancer, 12, 818–834.CrossRefPubMedPubMedCentral
36.
Floor, S. N., Condon, K. J., Sharma, D., Jankowsky, E., & Doudna, J. A. (2016). Autoinhibitory Interdomain interactions and subfamily-specific extensions redefine the catalytic core of the human DEAD-box protein DDX3. The Journal of Biological Chemistry, 291, 2412–2421.CrossRefPubMed
37.
Sengoku, T., Nureki, O., Nakamura, A., Kobayashi, S., & Yokoyama, S. (2006). Structural basis for RNA unwinding by the DEAD-box protein Drosophila Vasa. Cell, 125, 287–300.CrossRefPubMed
38.
Valentin-Vega, Y. A., Wang, Y. D., Parker, M., Patmore, D. M., Kanagaraj, A., Moore, J., Rusch, M., Finkelstein, D., Ellison, D. W., Gilbertson, R. J., Zhang, J., Kim, H. J., & Taylor, J. P. (2016). Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation. Scientific Reports, 6.
39.
Jones, R. G., & Thompson, C. B. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes & Development, 23, 537–548.CrossRef
40.
Welcker, M., & Clurman, B. E. (2008). FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Reviews Cancer, 8, 83–93.CrossRefPubMed
41.
Akhoondi, S., Sun, D., von der Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dofou, D., Marth, C., Mueller-Holzner, E., Corcoran, M., Dagnell, M., Nejad, S. Z., Nayer, B. N., Zali, M. R., Hansson, J., Egyhazi, S., Petersson, F., Sangfelt, P., Nordgren, H., Grander, D., Reed, S. I., Widschwendter, M., Sangfelt, O., & Spruck, C. (2007). FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Research, 67, 9006–9012.CrossRefPubMed
42.
White, K. A., Grillo-Hill, B. K., Esquivel, M., Peralta, J., Bui, V. N., Chire, I., & Barber, D. L. (2018). β-Catenin is a pH sensor with decreased stability at higher intracellular pH. The Journal of Cell Biology, 217, 3965–3976.CrossRefPubMedPubMedCentral
43.
Isom, D. G., Castaneda, C. A., Cannon, B. R., & Garcia-Moreno, B. (2011). Large shifts in pKa values of lysine residues buried inside a protein. Proceedings of the National Academy of Sciences of the United States of America, 108, 5260–5265.CrossRefPubMedPubMedCentral
44.
Castaneda, C. A., et al. (2009). Molecular determinants of the pKa values of Asp and Glu residues in staphylococcal nuclease. Proteins, 77, 570–588.CrossRefPubMed
45.
Fang, Y., Liu, Z., Chen, Z., Xu, X., Xiao, M., Yu, Y., Zhang, Y., Zhang, X., du, Y., Jiang, C., Zhao, Y., Wang, Y., Fan, B., Terheyden-Keighley, D., Liu, Y., Shi, L., Hui, Y., Zhang, X., Zhang, B., Feng, H., Ma, L., Zhang, Q., Jin, G., Yang, Y., Xiang, B., Liu, L., & Zhang, X. (2017). Smad5 acts as an intracellular pH messenger and maintains bioenergetic homeostasis. Cell Research, 27, 1083–1099.CrossRefPubMedPubMedCentral
46.
Vercoulen, Y., Kondo, Y., Iwig, J. S., Janssen, A. B., White, K. A., Amini, M., Barber, D. L., Kuriyan, J., & Roose, J. P. (2017). A histidine pH sensor regulates activation of the Ras-specific guanine nucleotide exchange factor RasGRP1. Elife, 6, e29002.CrossRefPubMedPubMedCentral
47.
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Research, 65, 10992–11000.CrossRefPubMed
48.
49.
Huang, C. H., Mandelker, D., Gabelli, S. B., & Amzel, L. M. (2008). Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle, 7, 1151–1156.CrossRefPubMed
50.
Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C. H., Kinzler, K. W., Vogelstein, B., & Amzel, L. M. (2009). A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proceedings of the National Academy of Sciences of the United States of America, 106, 16996–17001.CrossRefPubMedPubMedCentral
51.
Miled, N., Yan, Y., Hon, W. C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science, 317, 239–242.CrossRefPubMed
52.
Zhao, L., & Vogt, P. K. (2010). Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle, 9, 596–600.CrossRefPubMed
53.
Hatsell, S. J., Idone, V., Wolken, D. M. A., Huang, L., Kim, H. J., Wang, L., Wen, X., Nannuru, K. C., Jimenez, J., Xie, L., Das, N., Makhoul, G., Chernomorsky, R., D’Ambrosio, D., Corpina, R. A., Schoenherr, C. J., Feeley, K., Yu, P. B., Yancopoulos, G. D., Murphy, A. J., & Economides, A. N. (2015). ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Science Translational Medicine, 7, 303ra137–303ra137.CrossRefPubMedPubMedCentral
54.
Haupt, J., Stanley, A., McLeod, C. M., Cosgrove, B. D., Culbert, A. L., Wang, L., Mourkioti, F., Mauck, R. L., & Shore, E. M. (2018). ACVR1R206H FOP mutation alters mechanosensing and tissue stiffness during heterotopic ossification. Molecular Biology of the Cell (MBoC), 30, 17–29. https://​doi.​org/​10.​1091/​mbc.​E18-05-0311.CrossRef
55.
Buczkowicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L., Dzamba, M., Morrison, A., Lewis, P., Bouffet, E., Bartels, U., Zuccaro, J., Agnihotri, S., Ryall, S., Barszczyk, M., Chornenkyy, Y., Bourgey, M., Bourque, G., Montpetit, A., Cordero, F., Castelo-Branco, P., Mangerel, J., Tabori, U., Ho, K. C., Huang, A., Taylor, K. R., Mackay, A., Bendel, A. E., Nazarian, J., Fangusaro, J. R., Karajannis, M. A., Zagzag, D., Foreman, N. K., Donson, A., Hegert, J. V., Smith, A., Chan, J., Lafay-Cousin, L., Dunn, S., Hukin, J., Dunham, C., Scheinemann, K., Michaud, J., Zelcer, S., Ramsay, D., Cain, J., Brennan, C., Souweidane, M. M., Jones, C., Allis, C. D., Brudno, M., Becher, O., & Hawkins, C. (2014). Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 46, 451–456.CrossRefPubMedPubMedCentral
56.
Papadopoulos, T., Schemm, R., Grubmüller, H., & Brose, N. (2015). Lipid binding defects and perturbed synaptogenic activity of a collybistin R290H mutant that causes epilepsy and intellectual disability. The Journal of Biological Chemistry, 290, 8256–8270.CrossRefPubMedPubMedCentral
Metadata
Title
Intracellular pH dynamics and charge-changing somatic mutations in cancer
Authors
Katharine A. White
Kyle Kisor
Diane L. Barber
Publication date
01-06-2019
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2019
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-019-09791-8

Other articles of this Issue 1-2/2019

Cancer and Metastasis Reviews 1-2/2019 Go to the issue

OriginalPaper

What is pH regulation, and why do cancer cells need it?

ReviewPaper

Molecular and functional imaging insights into the role of hypoxia in cancer aggression

Correction

Correction to: Tumor pH and metastasis: a malignant process beyond hypoxia

NON-THEMATIC REVIEW

Exosomes, metastases, and the miracle of cancer stem cell markers

ReviewPaper

Cause and effect of microenvironmental acidosis on bone metastases

Correction

Correction to: mTOR co-targeting strategies for head and neck cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits